# TL-895

| | |
|---|---|
| **Cat. No.:** | HY-139481 |
| **CAS No.:** | 1415823-49-2 |
| **Molecular Formula:** | $C_{25}H_{26}FN_5O_2$ |
| **Molecular Weight:** | 447.5 |
| **Target:** | Btk |
| **Pathway:** | Protein Tyrosine Kinase/RTK |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 6 months<br>-20°C 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 250 mg/mL (558.66 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.2346 mL | 11.1732 mL | 22.3464 mL |
| | 5 mM | 0.4469 mL | 2.2346 mL | 4.4693 mL |
| | 10 mM | 0.2235 mL | 1.1173 mL | 2.2346 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an $IC_{50}$ and a $K_i$ of 1.5 nM and 11.9 nM, respectively[1]. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research[2][3][4].

**$IC_{50}$ & Target**

IC50: 1.5 nM;
Ki: 11.9 nM (BTK)[1]

## REFERENCES

[1]. Valeria Di Battista, et al. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int J Mol Sci

[2]. A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

[3]. Study of TL-895 in Subjects With Myelofibrosis

[4]. Richard D Caldwell, et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Sep 12;62(17):7643-7655.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA